Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV.
adherence
antiretroviral therapy
dried blood spots
low-level viremia
tenofovir diphosphate
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
13
07
2021
accepted:
03
09
2021
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
30
9
2021
Statut:
epublish
Résumé
The drivers of low-level viremia (LLV) between 20 and 200 copies/mL remain unclear. In 1042 person-visits from 497 persons with HIV on tenofovir disoproxil fumarate-containing antiretroviral therapy (ART), the association between LLV and cumulative antiretroviral adherence (quantified using tenofovir diphosphate [TFV-DP] in dried blood spots) was assessed. Lower TFV-DP levels were associated with higher odds of LLV. As TFV-DP (fmol/punch) categories decreased from >1650 to 800-1650; 800-1650 to <800; and >1650 to <800, the adjusted odds ratios for LLV vs HIV VL <20 copies/mL were 2.0 (95% CI, 1.2-3.1), 2.4 (95% CI, 1.1-5.0), and 4.6 (95% CI, 2.2-9.9), respectively. This suggests that adherence could impact LLV.
Identifiants
pubmed: 34584902
doi: 10.1093/ofid/ofab463
pii: ofab463
pmc: PMC8465325
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab463Subventions
Organisme : NIAID NIH HHS
ID : K23 AI104315
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
pubmed: 22935078
J Infect Dis. 2019 Jul 19;220(4):635-642
pubmed: 30942881
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
HIV Clin Trials. 2004 Mar-Apr;5(2):74-9
pubmed: 15116282
J Infect Dis. 2018 Jun 20;218(2):234-238
pubmed: 29529230
Pragmat Obs Res. 2017 May 26;8:91-97
pubmed: 28603436
J Infect Dis. 2007 Dec 15;196(12):1773-8
pubmed: 18190257
J Antimicrob Chemother. 2008 Mar;61(3):699-704
pubmed: 18192682
Open Forum Infect Dis. 2015 Jan 14;2(1):ofu119
pubmed: 25884007
J Antimicrob Chemother. 2020 Oct 1;75(10):2981-2985
pubmed: 32642769
J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):311-318
pubmed: 30893125
J Infect Dis. 2004 Apr 15;189(8):1487-96
pubmed: 15073687
AIDS. 2014 Jan 14;28(2):181-186
pubmed: 24361679
AIDS. 2019 Nov 1;33(13):2005-2012
pubmed: 31306175
Antimicrob Agents Chemother. 2014 Jul;58(7):3585-98
pubmed: 24733471
J Pharm Biomed Anal. 2016 Apr 15;122:16-20
pubmed: 26829517
J Infect Dis. 2012 Nov;206(9):1443-52
pubmed: 22927449
AIDS. 2015 Jan 28;29(3):373-83
pubmed: 25686685
Clin Infect Dis. 2013 Nov;57(10):1489-96
pubmed: 23946221
Clin Infect Dis. 2019 Apr 8;68(8):1335-1342
pubmed: 30137238
JAMA. 2005 Feb 16;293(7):817-29
pubmed: 15713771
Ther Adv Infect Dis. 2021 May 14;8:20499361211010596
pubmed: 34035910